Trial of Covid-19 blood plasma finds no benefit in severely ill patients | The Business Standard
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
The Business Standard

Friday
September 22, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
FRIDAY, SEPTEMBER 22, 2023
Trial of Covid-19 blood plasma finds no benefit in severely ill patients

Coronavirus chronicle

Reuters
11 January, 2021, 08:10 pm
Last modified: 11 January, 2021, 08:18 pm

Related News

  • Covid-19 economic impact lingers on in parts of society: Study
  • Jill Biden positive for Covid, President Biden tests negative: White House
  • China will not require Covid-19 testing for incoming travelers
  • Global Covid-19 incidence up by over 60% in 28 days: WHO
  • Pandemic, inflation push 68 million more in Asia into extreme poverty: ADB

Trial of Covid-19 blood plasma finds no benefit in severely ill patients

The underlying hypothesis for using convalescent plasma as a potential treatment for Covid-19 patients is that the antibodies it contains could neutralize the virus, stopping it from replicating and halting tissue damage

Reuters
11 January, 2021, 08:10 pm
Last modified: 11 January, 2021, 08:18 pm
Representational image. Photo: Collected
Representational image. Photo: Collected

An international trial testing convalescent blood plasma on Covid-19 patients with moderate and severe illness has halted enrolment of severely ill Covid-19 patients requiring intensive care after it found no benefit, trial investigators said on Monday.

The decision by the REMAP-CAP trial leaders came after an initial analysis of more than 900 severely ill trial participants in intensive care showed that treatment with the product - an antibody-rich plasma taken from people who have recovered from the pandemic disease - did not improve outcomes.

"There was no evidence of harm associated with the administration of convalescent plasma" (and) the trial is continuing to recruit hospitalised Covid-19 patients who are moderately ill but not in intensive care, scientists leading the trial said in a statement.

"It is biologically plausible that patients who are not producing antibodies at the time of convalescent plasma therapy and those patients with excess virus may benefit more than others. Our additional analyses will explore this," said Manu Shankar-Hari, a clinician and professor of critical care medicine at Britain's Guy's and St Thomas' hospital, who is co-leading the trial.

He added that the initial analysis did not assess plasma's effects in hospitalised patients with less severe disease. This "remains a very important question" and would continue to be explored in the ongoing trial, he said.

The underlying hypothesis for using convalescent plasma as a potential treatment for Covid-19 patients is that the antibodies it contains could neutralize the virus, stopping it from replicating and halting tissue damage.

But this initial analysis leading to the REMAP-CAP pause in enrolment of critically ill patients showed there was a very low probability - 2.2% - that it reduced death rates or decreased the number of days patients needed intensive care.

"Why convalescent plasma does not seem to improve outcome in severely ill Covid-19 patients admitted to the ICU is not yet known. However, it may be because the lung damage is too advanced for convalescent plasma to make a difference," said Alexis Turgeon, a critical care doctor and professor at Université Laval in Canada, who is also working on the trial.

REMAP-CAP is an international clinical trial exploring potential treatments for Covid-19. It has already recruited 4,100 Covid-19 patients at more than 290 clinical sites across Europe, the Americas, Asia, Africa and Australasia.

Separate findings from REMAP-CAP showed last week that treating critically ill Covid-19 patients with Roche's Actemra or Sanofi's Kevzara arthritis drugs significantly improved survival rates and reduced the amount of time patients need intensive care.

The trial is also looking at potential effects of a range of other existing therapies, including anticoagulation medicines, antiplatelet agents, antibiotics, statins and vitamin C.

Top News

COVID-19 / Covid-19 Plasma Therapy

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Photo: @UnderSecStateJ/X
    PM Hasina, Uzra Zeya meet; discuss importance of free, fair elections
  • Workers collect indigo leaves at a farm in Rangpur Sadar upazila. An important source of natural infigo dye in the 19th century in colonial India, the plant is seeing a revival through researchers and enthusiasts. The photo was taken recently. Photo: Khorshed Alam
    Indigo farming: Once a dark history, now a blessing
  • Illustration: TBS
    'Stop subsidising the status quo to avoid middle-income trap'

Related News

  • Covid-19 economic impact lingers on in parts of society: Study
  • Jill Biden positive for Covid, President Biden tests negative: White House
  • China will not require Covid-19 testing for incoming travelers
  • Global Covid-19 incidence up by over 60% in 28 days: WHO
  • Pandemic, inflation push 68 million more in Asia into extreme poverty: ADB

Features

Why is the fixed exchange rate for dollars failing?

Why is the fixed exchange rate for dollars failing?

1d | Panorama
At present, there are about 200 freezing vans operating in Dhaka city. Photo: Nayem Ali

Rising temperature is driving up the use of freezing vans

4h | Features
Illustration: TBS

'Stop subsidising the status quo to avoid middle-income trap'

4h | Panorama
Mountain gorillas are vulnerable species, only found in the willderness. Photo: Muntasir Akash

Against all odds: My encounters with mountain gorillas in Rwanda

22h | Earth

More Videos from TBS

After almost two months, the Ukrainian grain ship left the Black Sea port

After almost two months, the Ukrainian grain ship left the Black Sea port

17h | TBS World
Revenue collection rises 15% in first two months of FY24

Revenue collection rises 15% in first two months of FY24

14h | TBS Economy
Fans call for Amir’s inclusion after Naseem Shah's injury

Fans call for Amir’s inclusion after Naseem Shah's injury

15h | TBS SPORTS
The need for a circular economy in Bangladesh

The need for a circular economy in Bangladesh

18h | TBS Face to Face
EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]